Identification of Prognostic Alternative Splicing Signature in Gastric Cancer

Overview

Journal Arch Public Health

Publisher Biomed Central

Date 2022 May 25

PMID 35614517

Authors

Zhiwu Wang

Qiong Wu

Yankun Liu

Qingke Li

Jingwu Li

Affiliations

Soon will be listed here.

Abstract

Background: Aberrant alternative splicing (AS) events could be viewed as prognostic indicators in a large number of malignancies. This study aims to identify prognostic AS events, illuminate the function of the splicing variants biomarkers and provide reliable evidence for formulating public health strategies for gastric cancer (GC) surveillance.

Methods: RNA-Seq data, clinical information and percent spliced in (PSI) values were available in The cancer genome atlas (TCGA) and TCGA SpliceSeq data portal. A three-step regression method was conducted to identify prognostic AS events and construct multi-AS-based signatures. The associations between prognostic AS events and splicing factors were also investigated.

Results: We identified a total of 1,318 survival-related AS events in GC, parent genes of which were implicated in numerous oncogenic pathways. The final prognostic signatures stratified by seven types of AS events or not stratified performed well in risk prediction for GC patients. Moreover, five signatures based on AA, AD, AT, ES and RI events function as independent prognostic indicators after multivariate adjustment of other clinical variables. Splicing network also showed marked correlation between the expression of splicing factors and PSI value of AS events in GC patients.

Conclusion: Our findings provide a landscape of AS events and regulatory network in GC, indicating that AS events might serve as prognostic biomarkers and therapeutic targets for GC.

Citing Articles

Alternative splicing of mediated by genetic variants is significantly associated with endometrial cancer risk.

He S, Cao R, Mao Y, Li N, Wang Y, Ma H J Gynecol Oncol. 2023; 34(3):e40.

PMID: 36731897 PMC: 10157344. DOI: 10.3802/jgo.2023.34.e40.

References

Zong Z, Li H, Yi C, Ying H, Zhu Z, Wang H . Genome-Wide Profiling of Prognostic Alternative Splicing Signature in Colorectal Cancer. Front Oncol. 2018; 8:537. PMC: 6262947. DOI: 10.3389/fonc.2018.00537. View

Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A . SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia. 2018; 32(12):2659-2671. PMC: 6274620. DOI: 10.1038/s41375-018-0152-7. View

Yang Y, Qu A, Zhao R, Hua M, Zhang X, Dong Z . Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018; 12(12):2072-2084. PMC: 6275280. DOI: 10.1002/1878-0261.12385. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Bejar R . Splicing Factor Mutations in Cancer. Adv Exp Med Biol. 2016; 907:215-28. DOI: 10.1007/978-3-319-29073-7_9. View

Seiler M, Peng S, Agrawal A, Palacino J, Teng T, Zhu P . Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep. 2018; 23(1):282-296.e4. PMC: 5933844. DOI: 10.1016/j.celrep.2018.01.088. View

Li J, Feng D, Gao C, Zhang Y, Xu J, Wu M . Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway. Int J Oncol. 2019; 54(5):1591-1600. PMC: 6438423. DOI: 10.3892/ijo.2019.4728. View

Liang X, Chen W, Shi H, Gu X, Li Y, Qi Y . PTBP3 contributes to the metastasis of gastric cancer by mediating CAV1 alternative splicing. Cell Death Dis. 2018; 9(5):569. PMC: 5948206. DOI: 10.1038/s41419-018-0608-8. View

Dvinge H, Kim E, Abdel-Wahab O, Bradley R . RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016; 16(7):413-30. PMC: 5094465. DOI: 10.1038/nrc.2016.51. View

10.

Zhao D, Zhang C, Jiang M, Wang Y, Liang Y, Wang L . Survival-associated alternative splicing signatures in non-small cell lung cancer. Aging (Albany NY). 2020; 12(7):5878-5893. PMC: 7185095. DOI: 10.18632/aging.102983. View

11.

Liu C, Hu C, Li Z, Feng J, Huang J, Yang B . Systematic profiling of alternative splicing in -negative gastric cancer and their clinical significance. Cancer Cell Int. 2020; 20:279. PMC: 7325377. DOI: 10.1186/s12935-020-01368-8. View

12.

Martinez-Montiel N, Rosas-Murrieta N, Anaya Ruiz M, Monjaraz-Guzman E, Martinez-Contreras R . Alternative Splicing as a Target for Cancer Treatment. Int J Mol Sci. 2018; 19(2). PMC: 5855767. DOI: 10.3390/ijms19020545. View

13.

Armero V, Tremblay M, Allaire A, Boudreault S, Martenon-Brodeur C, Duval C . Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas. PLoS One. 2017; 12(5):e0176880. PMC: 5426614. DOI: 10.1371/journal.pone.0176880. View

14.

Marzese D, Manughian-Peter A, Orozco J, Hoon D . Alternative splicing and cancer metastasis: prognostic and therapeutic applications. Clin Exp Metastasis. 2018; 35(5-6):393-402. DOI: 10.1007/s10585-018-9905-y. View

15.

Zhou Y, Zhu G, Zhang Q, Zheng K, Chen J, Zhang X . Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. DNA Cell Biol. 2019; 38(11):1207-1222. DOI: 10.1089/dna.2019.4862. View

16.

Yang F, Xu J, Li H, Tan M, Xiong X, Sun Y . FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. Nat Commun. 2019; 10(1):1382. PMC: 6437151. DOI: 10.1038/s41467-019-09289-5. View

17.

Chen M, Zhang K, Gao B, Yang J, Tian Y, Das D . Phylogenetic comparison of 5' splice site determination in central spliceosomal proteins of the U1-70K gene family, in response to developmental cues and stress conditions. Plant J. 2020; 103(1):357-378. DOI: 10.1111/tpj.14735. View

18.

Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z . Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017; 393:40-51. DOI: 10.1016/j.canlet.2017.02.016. View

19.

Li Y, Gao X, Wei C, Guo R, Xu H, Bai Z . Modification of Mcl-1 alternative splicing induces apoptosis and suppresses tumor proliferation in gastric cancer. Aging (Albany NY). 2020; 12(19):19293-19315. PMC: 7732305. DOI: 10.18632/aging.103766. View

20.

Li S, Hu Z, Zhao Y, Huang S, He X . Transcriptome-Wide Analysis Reveals the Landscape of Aberrant Alternative Splicing Events in Liver Cancer. Hepatology. 2018; 69(1):359-375. DOI: 10.1002/hep.30158. View